(Nasdaq: BDSX), a leading diagnostics solutions company, announced the publication of the largest lung nodule biomarker clinical validation study ever conducted. This milestone strengthens the ...

Seventy-one percent of counties that spray the most glyphosate have late-stage non-Hodgkin lymphoma incidence rates above the national average, according to a new data analysis from the advocacy ...

Crosetto Foundation calls for transparency at the 2026 Total Body PET Conference to evaluate technology capable of detecting early-stage cancer currently missed by existing systems ...

Pancreatic cancer is known as one of the most dangerous cancers because it often develops quietly. Many people do not notice ...

Braylen Wimmer had surgery for a brain tumor in November. With the support of friends and family, he's worked his way back to baseball.

Nano-therapeutics represent a transformative advancement in precision cancer medicine, offering the promise of more effective and targeted treatment options. By harnessing the unique properties of ...

Novartis struck a deal valued at up to $3 billion to buy an experimental breast-cancer drug from Synnovation Therapeutics, moving to bolster its oncology pipeline with a new treatment approach. The ...

Boundless Bio's first direct ecDNA-targeting asset, is entering clinical trials with promising preclinical efficacy. Check out why BOLD stock is a buy.

Developing the system required careful fine-tuning. Too much stimulation can wear out immune cells, while too little allows them to lose function. The researchers optimized the strength of activation ...

A new form of CAR T kills leukemia, multiple myeloma, and sarcoma in mice, opening the door to a future off-the-shelf cancer treatment without chemotherapy.

The current path to CAR-T cell therapy is, by any measure, a logistical ordeal. A patient’s immune cells must be drawn out of ...